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INTRODUCTION 
 Hyperthermia is a key clinical outcome from recreational 
use of MDMA and is the leading cause of MDMA related 
hospital admissions as well as being linked to enhanced 
neurotoxicity [1, 2]. Animal models of ischemia which also 
display hyperthermia have shown an inflammatory process 
mediated by microglia and the release of the pro-
inflammatory cytokine interleukin 1- (IL-1) play a role in 
hyperthermicreactions [3]. Previous studies showed that 
microglia is prominently activated and IL-1 levels 
increased following MDMA administration [4], lending 
support to the hypothesis microglia play a role in MDMA 
induced hyperthermia. Minocycline is a tetracycline 
antibiotic with powerful anti-inflammatory properties, 
thought to be a result of its ability to attenuate glial 
activation [5]. This study examined whether preventing 
microglial activation through the administration of 
minocycline could limit or prevent the hyperthermia induced 
by MDMA. 
METHODS 
 Male Sprague-Dawley rats were treated daily with 50 
mg/kg i.p. of minocycline (or vehicle control) for two or 
three days (Fig. 1). 30 min following the final dose they 
were administered 10 mg/kg i.p. of MDMA with core body 
temperature and behavioral measurements taken every half 
hour (from 2 hr prior to 4 hr post MDMA treatment). 
Experiments were conducted at a normal ambient 
temperature of 22°C. The animals were then anaesthetised 
with Chloral Hydrate (400mg/kg i.p.), core blood was taken 
and the brain quickly removed and stored at -70°C. Blood 
and brain levels of MDMA and its major metabolite 3,4-
methylendioxyamphetamine (MDA) were measured using 
HPLC-ED and levels of IL-1 in the cortex and striatum 
were analysed using an ELISA assay. Temperature 
measurements and IL-1 levels were analysed using a two-
way ANOVA with Bonferroni’s post-hoc test. Plasma and 
brain levels of MDMA and MDA were analysed using one-
way ANOVA with Tuckey’s post-test. Behavioural data was 
compared using the Kruskal-Wallis test. P < 0.05 was taken 
as significant for all analyses. 
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RESULTS 
 MDMA treated animals showed significant increases in 
core temperature compared with rats treated with saline (p = 
0.0001, n=6). Minocycline alone had no significant effect on 
core temperature. Animals administered MDMA and 
minocycline had a significantly reduced rise in temperature 
compared to MDMA treated animals (p<0.01, n=6). 
Behavioural measures showed no significant differences 
between animals receiving minocycline and those not, but 
did between MDMA and saline treated animals (n=6, 
P<0.0001). Minocycline had no significant effect on either 
blood (p =0.940, n=8) or brain (p =0.9296, n=8) 
concentrationsof MDMA and MDA. An interleukin 1-beta 
assay was performed on cortex, this showed no significant 
differences between any of the treatment groups, (p = 
0.5235, n=4). 
 
Fig. (1). Effect of MDMA co-administered with minocycline (2 day 
treatment [2x Min] or 3 day treatment [3x Min]) on core body 
temperature, represented as the change from baseline temperature 
(mean of temperature recorded at -60, -30 and 0 mins). Saline (Sal) 
or Min was administered at –30 min; Sal or MDMA (10 mg/kg, 
i.p.) was administered at 0 min. Data are given as mean + SEM (n = 
6). 
DISCUSSION 
 The major findings of this study are that the pre-
treatment administration of minocycline significantly 
attenuates the hyperthermia induced by MDMA 
administration in rats. Minocycline also had no significant 
impact on MDMA-induced behavioural stimulation, 
supporting the hypothesis that an inflammatory response 
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plays a role in MDMA induced hyperthermia; independent  
 
of serotonin and dopamine mediated behavioural stimu-
lation. Further evidence in support of this hypothesis is the 
finding of similar brain and plasma concentrations of 
MDMA and MDA with and without the co-administration of 
minocycline. Both compounds were detected at similar 
levels regardless of minocycline treatment indicating that 
minocycline’s action is not due to changes in MDMA 
pharmacokinetics. 
CONCLUSION 
 The results of this study indicate that the mechanisms 
underlying MDMA induced hyperthermia may include an 
inflammatory response mediated by microglia. These results 
also indicate that immune status may be a factor in the 
apparently idiosyncratic effects of MDMA on hyperthermia 
in some individuals and as such preventing or inhibiting glial 
activation may be a clinically relevant method of treating 
MDMA toxicity. 
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